FDA approves GSK drug for endometrial cancer with specific genetic signature

FDA approves GSK drug for endometrial cancer with specific genetic signature

Source: 
MedCity News
snippet: 

The FDA approved GlaxoSmithKlie drug dostarlimab (Jemperli) for endometrial cancer that carries a particular genetic signature. The immunotherapy now joins Merck's Keytruda as the checkpoint inhibitors approved for treating endometrial cancer.